Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
MRK Merck & Co., Inc. weekly Stock Chart
MRK [NYSE]
Merck & Co., Inc.
Healthcare | Drug Manufacturers - Major | USA
statements
IndexDJIA S&P500 P/E22.27 EPS (ttm)3.71 Insider Own0.10% Shs Outstand2.58B Perf Week-4.57%
Market Cap213.30B Forward P/E15.10 EPS next Y5.47 Insider Trans-21.33% Shs Float2.56B Perf Month-0.95%
Income9.72B PEG2.19 EPS next Q1.23 Inst Own78.60% Short Float0.85% Perf Quarter-0.21%
Sales44.37B P/S4.81 EPS this Y33.00% Inst Trans0.12% Short Ratio2.22 Perf Half Y1.27%
Book/sh10.74 P/B7.69 EPS next Y11.47% ROA11.20% Target Price96.33 Perf Year18.25%
Cash/sh2.75 P/C30.02 EPS next 5Y10.17% ROE32.80% 52W Range66.10 - 87.35 Perf YTD8.11%
Dividend2.20 P/FCF89.32 EPS past 5Y10.60% ROI11.70% 52W High-6.32% Beta0.53
Dividend %2.66% Quick Ratio0.90 Sales past 5Y-0.80% Gross Margin71.10% 52W Low23.80% ATR1.69
Employees69000 Current Ratio1.20 Sales Q/Q12.40% Oper. Margin26.70% RSI (14)38.87 Volatility2.79% 1.75%
OptionableYes Debt/Eq0.96 EPS Q/Q62.90% Profit Margin21.10% Rel Volume0.47 Prev Close82.61
ShortableYes LT Debt/Eq0.82 EarningsOct 29 BMO Payout59.20% Avg Volume9.84M Price81.83
Recom1.70 SMA20-4.06% SMA50-2.57% SMA2001.99% Volume2,306,566 Change-0.94%
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Sep-16-19 09:16AM  Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy? Zacks
08:33AM  Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert Zacks
06:30AM  BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia GlobeNewswire
Sep-13-19 05:27PM  Roche's New Perjeta Combo Meets Goal in Breast Cancer Study Zacks
09:36AM  Renal Cell Carcinoma Space in Focus: Some Key Developments Zacks
04:47AM  Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised) Zacks
04:33AM  Stocks - Broadcom, Merck Fall in Premarket; Amazon Rises Investing.com
Sep-12-19 05:46PM  Gilead Tops List of Most Innovative Drug Companies GuruFocus.com
03:10PM  Reuters asks judge to release secret Propecia documents Reuters
02:48PM  Reuters asks judge to release secret Propecia documents Reuters
10:50AM  Momentum ETFs & Stocks in Focus as Trump Delays Tariff Hike Zacks
10:02AM  Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus Zacks
09:09AM  Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug Zacks
Sep-11-19 05:45PM  Merck (MRK) Outpaces Stock Market Gains: What You Should Know Zacks
11:13AM  Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit Zacks
09:32AM  4 Big Drugmakers Boasting Impressive Oncology Pipelines Zacks
09:24AM  Merck Sees Hammer Chart Pattern: Time to Buy? Zacks
08:57AM  The Zacks Analyst Blog Highlights: Microsoft, Merck, Procter & Gamble, United Technologies and Coca-Cola Zacks
06:34AM  Merck Shares Could Trade Sideways Before Renewed Gains TheStreet.com
04:00AM  Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane Reuters
02:30AM  Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations PR Newswire
02:30AM  Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations PR Newswire
Sep-10-19 06:06PM  Pfizer's Pneumococcal Vaccine Shows Potential in Infants Zacks
12:08PM  Mercks $14 Billion Market-Value Plunge Is More Than Last Quarters Revenue Bloomberg
11:41AM  ACADIA Surges on Early Success of Nuplazid Dementia Study Zacks
10:00AM  Merck, Pfizer Slide on Pelosis Scary Drug-Pricing Plan Bloomberg
08:00AM  Merck Announces First Nine Safer Childbirth Cities Committed to Reducing Maternal Deaths and Narrowing Disparities in the US Business Wire
07:11AM  Buy 5 Top Dow Stocks to Gain From Index's Rally Zacks
06:45AM  Pooled Analysis Continues to Show Mercks KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Advanced NSCLC Whose Tumors Do Not Express PD-L1 Business Wire
Sep-09-19 06:05PM  Tech Stocks Fall Monday With New Tech Probes GuruFocus.com
05:33PM  BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49 GlobeNewswire
04:39PM  Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study Zacks
11:33AM  The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers Zacks
09:24AM  Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks? Investor's Business Daily
08:00AM  Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019 PR Newswire
06:45AM  Pivotal New Data from Mercks Broad Oncology Portfolio at ESMO 2019 Congress Business Wire
06:12AM  Income Investors Should Know That Merck & Co., Inc. (NYSE:MRK) Goes Ex-Dividend Soon Simply Wall St.
03:38AM  CORRECTED-AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer Reuters
Sep-06-19 11:48AM  Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA Zacks
11:36AM  Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs Zacks
11:29AM  Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study Zacks
08:39AM  Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer Zacks
Sep-05-19 06:17PM  Top 6 Holdings of Jeremy Grantham's GMO GuruFocus.com
01:50PM  AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC Zacks
10:35AM  Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease Zacks
09:36AM  Merck's Keytruda Combination Gets EC Nod for Kidney Cancer Zacks
09:00AM  Pfizer Stock Is A Top Pharma Company But Should You Buy It? Investor's Business Daily
Sep-04-19 05:45PM  Merck (MRK) Stock Sinks As Market Gains: What You Should Know Zacks
08:00AM  Merck Foundation Launches Five-Year Initiative to Reduce Disparities in HIV Care for Vulnerable and Underserved Southeastern US Communities Business Wire
06:45AM  European Commission Approves Mercks KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC) Business Wire
Sep-03-19 12:59AM  Top Analyst Reports: Amazon, Merck, PepsiCo & More Zacks
Sep-02-19 08:01AM  Can Merck & Co., Inc.'s (NYSE:MRK) ROE Continue To Surpass The Industry Average? Simply Wall St.
Aug-30-19 11:16AM  AstraZeneca's Lupus Drug Meets Primary Endpoint in Study Zacks
10:26AM  Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study Zacks
10:21AM  AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails Zacks
Aug-29-19 09:31AM  Why Is Merck (MRK) Up 4.2% Since Last Earnings Report? Zacks
09:15AM  Why Merck (MRK) is a Top Dividend Stock for Your Portfolio Zacks
09:06AM  Forget Pfizer, Add These Big Drugmakers to Your Portfolio Zacks
Aug-28-19 03:25PM  FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck Reuters
10:15AM  Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion Zacks
10:10AM  Here's Why Merck (MRK) is Outperforming Its Industry Of Late Zacks
Aug-27-19 11:19AM  Medicines Company's Inclisiran Succeeds in Pivotal Study Zacks
10:59AM  Top Ranked Growth Stocks to Buy for August 27th Zacks
08:05AM  Bristol-Myers Announces Sale of Celgene's Otezla to Amgen Zacks
06:30AM  BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 GlobeNewswire
06:09AM  Stocks - Wall Street Rises With Trade Developments Eyed Investing.com
Aug-26-19 11:05AM  Esperion's Drugs in Review Hold Potential, Funds a Concern Zacks
09:01AM  Top Ranked Growth Stocks to Buy for August 26th Zacks
Aug-25-19 09:09AM  Congo has given over 200,000 people Merck Ebola vaccine-gov't Reuters
Aug-24-19 01:46PM  10 Biopharmaceutical Companies Trying To Cure Cancer Benzinga
Aug-23-19 02:37PM  Will Lawsuits Sink Johnson & Johnson Stock? InvestorPlace
08:27AM  Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer Zacks
Aug-22-19 06:08PM  AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China Zacks
12:10PM  Health insurers will expand ACA coverage in 2020 Yahoo Finance Video
10:20AM  Pfizer's Xtandi Label Expansion Filing Gets Priority Review Zacks
10:07AM  Glaxo Submits First Regulatory Application for Daprodustat Zacks
08:21AM  Analysts Share Stocks To Buy On Fed Uncertainty Benzinga
06:45AM  Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer Business Wire
Aug-21-19 04:10PM  Record Stock Buybacks Fueled by Debt and Cash GuruFocus.com
10:50AM  AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study Zacks
Aug-20-19 06:38PM  Bayer Sells Animal Health Division to Elanco: Now What? Zacks
12:01PM  Breaking down the debate for medicare for all Yahoo Finance Video
11:13AM  The Zacks Analyst Blog Highlights: Microsoft, Merck, Walmart, Coca-Cola and Visa Zacks
Aug-19-19 08:49AM  Buy 5 Dow Stocks That Have Surged Despite Market Gyrations Zacks
Aug-16-19 11:28AM  Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY Zacks
10:33AM  AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL Zacks
09:00AM  Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC Zacks
06:20AM  Gene therapies to test FDA's approach to regulating drugs after launch, experts say American City Business Journals
Aug-15-19 03:36PM  The Top Pharma Stocks for 2019 Investopedia
07:55AM  Moleculin Completes Enrollment in Early-Stage Cancer Study Zacks
07:48AM  Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth Zacks
06:32AM  New CEO named for Moffitt startup M2Gen American City Business Journals
Aug-14-19 04:32PM  Article removed GuruFocus.com
06:55AM  LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer Business Wire
Aug-13-19 09:15AM  Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice Zacks
07:27AM  GSK's new pharma president carries Merck, Pfizer experience American City Business Journals
06:00AM  An Intrinsic Calculation For Merck & Co., Inc. (NYSE:MRK) Suggests It's 22% Undervalued Simply Wall St.
Aug-12-19 07:15PM  Merck & Co Inc (MRK) EVP&Pres, Merck Animal Heallth Richard R. Deluca Sold $3. ... GuruFocus.com
12:10PM  Bristol-Myers Squibb Stock Has Upside But Mind the Risks InvestorPlace
09:30AM  J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients Zacks
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Intec Pharma Ltd.; Nerviano Medical Sciences; Healthy Interactions, Inc.; Oncologie, Inc.; and Themis Bioscience. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Option Exercise0.006,427077,951Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Sale85.096,427546,85071,524Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Option Exercise0.0031,6990103,223Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Sale85.0131,6992,694,78971,524Aug 12 05:13 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Option Exercise0.00216,7180354,378Jun 27 05:05 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Sale85.43216,71818,514,032137,660Jun 27 05:05 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 10Option Exercise0.003,292022,412May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 10Option Exercise0.004,389071,993May 13 05:05 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 10Option Exercise0.001,50903,317May 13 05:05 PM
Nally MichaelEVP, Chief Marketing OfficerMay 10Option Exercise0.001,81104,376May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Option Exercise39.2925,000982,25092,604May 09 06:11 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Sale77.7325,0001,943,18367,604May 09 06:11 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise0.005,77205,772May 07 07:42 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise0.001,29802,935May 07 07:40 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise0.001,904068,542May 07 07:37 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.001,212019,717May 07 08:32 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise0.0069202,046May 07 08:32 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Option Exercise39.2935,0001,375,150106,064May 07 08:33 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Sale80.0035,0002,800,00071,064May 07 08:33 PM
Merck & Co., Inc.10% OwnerApr 08Buy16.004,121,68365,946,92812,955,016Apr 09 06:27 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Option Exercise58.22192,57211,211,542330,232Mar 27 05:45 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Sale82.38192,57215,863,119137,660Mar 27 05:45 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Option Exercise39.29192,7367,572,597990,451Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Sale82.05192,73615,813,372797,715Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Option Exercise39.2918,725735,705816,440Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Sale82.0018,7251,535,454797,715Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Option Exercise39.296,961273,498804,676Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Sale82.006,961570,809797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Option Exercise39.2913,144516,428810,859Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Sale82.0113,1441,077,875797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Option Exercise39.2953,9612,120,128745,911Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Sale80.0253,9614,318,089691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Option Exercise39.2941,9921,649,866733,942Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Sale80.0041,9923,359,452691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Option Exercise39.2942,7001,677,683734,650Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Sale80.0242,7003,416,944691,950Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Option Exercise39.2992,9133,650,552784,863Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Sale80.0392,9137,436,162691,950Feb 19 05:35 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Option Exercise59.1664,6623,825,55180,837Feb 14 06:02 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale78.9664,6625,105,95116,175Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Option Exercise24.305,000121,5005,100Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Sale78.715,000393,548100Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Option Exercise38.1873,7272,815,241125,194Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Sale78.6273,7275,796,30651,467Feb 14 06:02 PM
BRUN LESLIE ADirectorFeb 08Option Exercise24.305,000121,5005,000Feb 11 05:33 PM
BRUN LESLIE ADirectorFeb 08Sale77.223,052235,6811,948Feb 11 05:33 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Option Exercise39.29231,5669,098,228923,516Feb 06 05:30 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Sale78.08231,56618,079,654691,950Feb 06 05:30 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Option Exercise44.98225,44310,140,426366,998Nov 08 04:31 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Sale75.27225,44316,967,967141,555Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise54.6836,2181,980,40082,481Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale75.1436,2182,721,34846,263Nov 08 04:31 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Option Exercise39.29277,87910,917,866277,879Nov 02 04:44 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Sale73.81277,87920,510,9450Nov 02 04:44 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Option Exercise58.3647,0362,745,21756,806Nov 01 05:07 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Sale74.3347,0363,496,1589,770Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Option Exercise34.1925,467870,71782,135Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Sale72.0025,4671,833,73956,668Nov 01 05:07 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Option Exercise36.56279,85010,231,316971,800Oct 03 05:26 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Sale72.07279,85020,168,258691,950Oct 03 05:26 PM
Merck & Co., Inc.10% OwnerOct 01Buy15.00666,6669,999,9902,723,509Oct 02 02:31 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
open in yahoo | open in reuters | open in google